The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Garzulys
insulin aspart-fsan · INSULIN ASPART 100 [iU]/mL · Injection, Solution · Subcutaneous · Meitheal Pharmaceuticals Inc.
NDC 71288-0903-81 · 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761497
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of insulin aspart-fsan (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Meitheal Pharmaceuticals Inc. | INSULIN ASPART 100 [iU]/mL | Aug 5, 2026 | Sep 3, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Garzulys — NDC 71288-0903-81," retrieved September 3, 2026, https://drugdashboards.com/drug/71288090381.
Free to cite with attribution — see how the data is put together.